Biographical summary
Yousef Zakharia, M.D., is a medical oncologist with clinical expertise in genitourinary malignancies and early phase experimental therapeutics. He joined Mayo Clinic AZ in September 2024 as Vice-Chair of the
Genitourinary Malignancy Disease Group, leading the Kidney Cancer Program at the Mayo Clinic Comprehensive Cancer Center. He is also the Medical Director of the Experimental Therapeutics Clinic at
Mayo Clinic AZ.
Prior to joining Mayo Clinic, Dr. Zakharia was on the faculty at the University of Iowa for the last 10 years and became a professor of medicine in 2024. He served as the Phase 1 Program Director at the Holden Comprehensive Cancer Center. Dr. Zakharia has been principal investigator on more than 50 clinical trials, including investigator-initiated trials (IITs), industry-sponsored studies, and cooperative group studies. His clinical and translational research has been published in reputable journals, including but not limited to NEJM, JCO, Nature Communications, Cancer Discovery, JITC, and CCR. He has presented his
work at multiple national and international meetings, including a plenary session at the American Association of Cancer Research (AACR) Annual Meeting in 2017.
One of his goals at Mayo Clinic is to work closely with the team to bring innovative clinical trials to our patients and to mentor fellows and junior faculty interested in clinical research.
        Conditions treated
        
        
        Mayo Clinic locations
        Education
- 2014Fellowship - Hematology/OncologyGeorgia Regents University 
- 2012Fellowship - Hematology and OncologyMichigan State University 
- 2011Residency - Internal MedicineUniversity of Rochester/Unity Hospital 
- 2007Residency - Diagnostic RadiologyDamascus University 
- 2005MDDamascus University School of Medicine 
Activities and honors
Certifications
- 2014Medical OncologyAmerican Board of Internal Medicine 
- 2011Internal MedicineAmerican Board of Internal Medicine 
Professional memberships
- 2024 - presentLeaderExperimental Therapeutics and Phase I Clinics 
- 2024 - presentVice ChairGenitourinary Malignancy Disease Group, Mayo Clinic Comprehensive Cancer Center 
- 2024 - presentLeaderKidney Cancer Program, Mayo Clinic Comprehensive Cancer Center 
- 2022 - 2024Co-ChairBig Ten Genitourinary Clinical Trial Working Group 
- 2022 - 2024Co-ChairORIEN Clinical Trials Network 
- 2021 - 2024MemberFaculty Senate Governmental Relations Committee, University of Iowa 
- 2019 - 2024MemberInstitutional Review Board, University of Iowa 
- 2017 - 2019Co-ChairImmunotherapy Clinical Trial Working Group, Big Ten Cancer Consortium 
- 2017 - presentMemberSociety of Immunotherapy of Cancer (SITC) 
- 2016 - 2020Board MemberBoard of Directors, Midwest Melanoma Partnership 
- 2014 - 2024MemberGenitourinary Malignancy Program, University of Iowa Holden Comprehensive Cancer Center 
- 2014 - 2020MemberProtocol Review and Monitoring Committee, University of Iowa Holden Comprehensive Cancer Center 
- 2013 - 2014MemberProtocol Review and Monitoring Committee, Georgia Regents University 
- 2011 - presentMemberAmerican Society of Clinical Oncology (ASCO) 
- 2011 - presentMemberAmerican Society of Hematology (ASH) 
- 2008 - presentMemberAmerican College of Physicians (ACP) 
- 2007 - presentMemberSyrian American Medical Society (SAMS) 
- 2005 - presentMemberSyrian Syndicate of Medicine 
Publications